Iron Chelation with Deferasirox in Two Patients with HFE Hemochromatosis and Chronic Anemia

By  

Acta Haematologica, Vol. 126, Iss. 2, 2011-06 ,pp. : 119-121

Karger

Access to resources Recommend Favorite

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 233-242

Karger

Access to resources Recommend Favorite

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1542-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom

By Karnon J.   Tolley K.   Oyee J.   Jewitt K.   Ossa D.   Akehurst R.  

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1609-1621

Informa Healthcare

Access to resources Recommend Favorite

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite